Table 2.

Monitoring Recommendations for BRAF and MEK Inhibitor Combinations

Drug Names	Monitoring Parameter	Frequency of Monitoring
Vemurafenib (Zelboraf) and Cobimetinib (Cotellic)	Dermatologic evaluation	Baseline, every 2 mo during treatment and up to 6 mo after discontinuation
	Electrocardiogram	Baseline, 15 d after initiation, monthly for 3 mo, then every 3 mo
	Cardiac function (left ventricular ejection fraction)	Baseline, 1 mo, and every 3 mo until discontinuation
	Basic metabolic panel	Baseline, then after dosage modifications and routinely during treatment
	Hepatic function and bilirubin	Baseline, then monthly
	Creatinine Phosphokinase	Baseline, then as clinically indicated
	Retinal evaluation	Baseline, then periodically during treatment and with visual disturbances
Dabrafenib (Tafinlar) and Trametinib (Mekinist)	Dermatologic evaluation	Baseline, every 2 mo during treatment and up to 6 mo after discontinuation
	Serum glucose	Routinely, particularly in patients with preexisting diabetes
	Cardiac function (left ventricular ejection fraction)	Baseline, 1 mo after initiation, then every 2 to 3 mo
	Blood pressure	Routinely during therapy
	Complete blood count	Baseline, then routinely during treatment
	Hepatic function tests	Baseline, then routinely during treatment
	Retinal evaluation	Periodically during treatment and with visual disturbances
Encorafenib (Braftovi) and Binimetinib (Mektovi)	Dermatologic evaluation	Baseline, every 2 mo during treatment and up to 6 mo after discontinuation
	Electrocardiogram	Baseline, then as clinically indicated
	Cardiac function (left ventricular ejection fraction)	Baseline, 1 mo, and every 2 to 3 mo during treatment
	Basic metabolic panel	Baseline, then routinely during treatment
	Hepatic function tests	Baseline, then monthly
	Creatinine phosphokinase	Baseline, then as clinically indicated

Abbreviation: MEK, mitogen-activated protein kinase kinase.